Other News

BD Announces Live Webcast Of Second Fiscal Quarter Earnings Conference Call

FRANKLIN LAKES, N.J., April 4, 2019 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX) announced today that it will conduct a live webcast of its second fiscal quarter 2019 earnings conference call on Thursday, May 9, 2019, at 8:00 a.m. (ET). BD will issue a press release detailing the quarter’s earnings earlier that morning. The […]

Cardiogenic Shock Survival Rates Improve Significantly in Three Years Since Impella FDA PMA Approval

DANVERS, Mass.–(BUSINESS WIRE)–Three years ago this week, Abiomed’s (NASDAQ: ABMD) Impella heart pumpreceived its FDA PMA approval for AMI cardiogenic shock. At the time of Impella’s FDA PMA approval, the cardiogenic shock survival rate to explant in the Impella Quality Assurance (IQ) Database was 51% in the United States1. Today, Impella heart pumps, combined […]

InspireMD, Inc. Announces Pricing of $2.4 Million Public Offering of Common Stock

Email Print Friendly Share April 04, 2019 06:00 ET | Source: InspireMD, Inc. TEL AVIV, Israel, April 04, 2019 (GLOBE NEWSWIRE) — InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced the pricing of its previously […]

HeartMate 3 heart pump reduces burden of bleeding and stroke rates, eliminates pump thrombosis

Orlando, Fla., April 04, 2019 (GLOBE NEWSWIRE) — Patients with a newer version of a common heart pump experienced a reduced aggregate burden of bleeding and stroke rates – and no pump thrombosis requiring surgical exchange, compared to patients with the predecessor device.  The MOMENTUM3 study was a randomized controlled […]

Milestone Pharmaceuticals Appoints Michael Tomsicek to Board of Directors

MONTREAL and CHARLOTTE, N.C., April 4, 2019 /PRNewswire/ — Milestone Pharmaceuticals, a late-stage biopharmaceutical company developing acute therapies for the treatment of episodic cardiovascular indications, today announced the appointment of Michael Tomsicek to its Board of Directors. Mr. Tomsicek is currently the Chief Financial Officer of CRISPR Therapeutics, a biopharmaceutical company focused on developing gene-based medicines. In addition […]

TherOx Receives FDA Approval for First Heart Attack Treatment Since PCI to Reduce Infarct Size

IRVINE, Calif.–(BUSINESS WIRE)–TherOx, Inc., a privately held medical device company focused on improving treatment of acute myocardial infarction (AMI), announced that the U.S. Food and Drug Administration (FDA) granted premarket approval for its SuperSaturated Oxygen (SSO2) Therapy. SSO2 Therapy provides interventional cardiologists with the first and only FDA-approved treatment beyond percutaneous […]

Tioga Medical, A Shifamed Portfolio Company, Closes $15M In Series A Financing

CAMPBELL, Calif., April 4, 2019 /PRNewswire/ — Tioga Medical, a newly formed Shifamed portfolio company, announced today the closing of its Series A preferred stock financing, raising a total of $15M. Tioga Medical was founded to provide physicians and patients with an elegant transcatheter valve replacement experience that is procedurally simpler and less invasive […]

Shockwave Completes Enrollment of Disrupt CAD II Study

SANTA CLARA, Calif., April 03, 2019 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, has completed enrollment of its DISRUPT CAD II study, a regulatory-required European post-market registry of coronary IVL. IVL is […]